{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:46Z","timestamp":1793298946905,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.05.015","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T19:49:54Z","timestamp":1780170594000},"page":"855-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["New Paradigms in Theranostics of Prostate Cancer: The Rise of \u03b1-Emitters and Next-generation Targets"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-7534","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"Deandreis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.05.015_b0005","doi-asserted-by":"crossref","unstructured":"Deandreis D, Jacene H, Therasse P, et al. Radiopharmaceutical therapy in oncology: perspectives from transatlantic experts. Oncol Ther. In press. https:\/\/doi.org\/10.1007\/s40487-026-00432-z.","DOI":"10.1007\/s40487-026-00432-z"},{"key":"10.1016\/j.euf.2026.05.015_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.015_b0015","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.05.015_b0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.semnuclmed.2025.09.005","article-title":"Development of PSMA-targeted alpha therapy using [211At]PSMA-5","volume":"55","author":"Watabe","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.euf.2026.05.015_b0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2967\/jnumed.124.269299","article-title":"First-in-human Phase 0 study of AB001, a prostate-specific membrane antigen-targeted 212Pb radioligand, in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Berner","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.015_b0030","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S1470-2045(25)00559-5","article-title":"Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial","volume":"26","author":"Kostos","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.015_b0035","doi-asserted-by":"crossref","unstructured":"Aras O, Berbero\u011flu K. First-in-human tandem terbium-161 and actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. In press. https:\/\/doi.org\/10.1007\/s00259-026-07785-7.","DOI":"10.1007\/s00259-026-07785-7"},{"key":"10.1016\/j.euf.2026.05.015_b0040","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2024.42.16_suppl.5010","article-title":"A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225 Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Morris","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.05.015_b0045","first-page":"5","article-title":"Phase 1 study of [177 Lu]Lu-NeoB in patients with advanced solid tumors overexpressing gastrin-releasing peptide receptor: preliminary safety and dosimetry results","volume":"67","author":"Mittra","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.015_b0050","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/1078-0432.CCR-24-2850","article-title":"Effective treatment of disseminated prostate cancer using CD46-targeted 225Ac therapy","volume":"31","author":"Bidkar","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:58:19Z","timestamp":1793296699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926000842"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.015","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Paradigms in Theranostics of Prostate Cancer: The Rise of \u03b1-Emitters and Next-generation Targets","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}